These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37180421)

  • 1. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review.
    Jain P; Badgujar L; Spoorendonk J; Buesch K
    Ther Adv Rare Dis; 2022; 3():26330040221139872. PubMed ID: 37180421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Brassington R; Pandolfo M
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD007791. PubMed ID: 27572719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
    Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
    Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants and other pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Pandolfo M
    Cochrane Database Syst Rev; 2012 Apr; (4):CD007791. PubMed ID: 22513953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
    Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidants and other pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Pandolfo M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007791. PubMed ID: 19821439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
    Lynch DR; Perlman SL; Meier T
    Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
    Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A
    Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales.
    Fahey MC; Corben L; Collins V; Churchyard AJ; Delatycki MB
    J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):411-3. PubMed ID: 17056635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open-label, prospective study.
    Qureshi MY; Patterson MC; Clark V; Johnson JN; Moutvic MA; Driscoll SW; Kemppainen JL; Huston J; Anderson JR; Badley AD; Tebben PJ; Wackel P; Oglesbee D; Glockner J; Schreiner G; Dugar S; Touchette JC; Gavrilova RH
    J Inherit Metab Dis; 2021 Mar; 44(2):502-514. PubMed ID: 32677106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FARS-ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change.
    Traschütz A; Fleszar Z; Hengel H; Klockgether T; Erdlenbruch F; Falkenburger BH; Klopstock T; Öztop-Çakmak Ö; Pedroso JL; Santorelli FM; Schöls L; ; Synofzik M
    Mov Disord; 2024 Jun; 39(6):965-974. PubMed ID: 38509638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the Validity of Conducting Rating Scales in Friedreich Ataxia through Video.
    Tai G; Corben LA; Woodcock IR; Yiu EM; Delatycki MB
    Mov Disord Clin Pract; 2021 Jul; 8(5):688-693. PubMed ID: 34307740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal gait and balance decline in Friedreich's Ataxia: A pilot study.
    Zesiewicz TA; Stephenson JB; Kim SH; Sullivan KL; Jahan I; Huang Y; Salemi JL; Wecker L; Shaw JD; Gooch CL
    Gait Posture; 2017 Jun; 55():25-30. PubMed ID: 28411441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.
    Bürk K; Schulz SR; Schulz JB
    J Neurochem; 2013 Aug; 126 Suppl 1():118-24. PubMed ID: 23859347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring Friedreich ataxia: complementary features of examination and performance measures.
    Lynch DR; Farmer JM; Tsou AY; Perlman S; Subramony SH; Gomez CM; Ashizawa T; Wilmot GR; Wilson RB; Balcer LJ
    Neurology; 2006 Jun; 66(11):1711-6. PubMed ID: 16769945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harmonizing results of ataxia rating scales: mFARS, SARA, and ICARS.
    Rummey C; Harding IH; Delatycki MB; Tai G; Rezende T; Corben LA
    Ann Clin Transl Neurol; 2022 Dec; 9(12):2041-2046. PubMed ID: 36394163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
    Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
    Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.